Safeguard Scientifics (SFES) 10-K 5 Mar 21 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Feb. 26, 2021	Jun. 30, 2020
Document Information [Line Items]
Entity Central Index Key	0000086115
Entity Registrant Name	SAFEGUARD SCIENTIFICS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Document Transition Report	false
Entity File Number	1-5620
Entity Incorporation, State or Country Code	PA
Entity Tax Identification Number	23-1609753
Entity Address, Address Line One	150 N. Radnor Chester Road
Entity Address, City or Town	Radnor
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19087
City Area Code	610
Local Phone Number	293-0600
Title of 12(b) Security	Common Stock ($.10 par value)
Trading Symbol	SFE
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 136,021,431
Entity Common Stock, Shares Outstanding		20,944,305

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 15,601	$ 25,028
Restricted cash	0	25
Prepaid expenses and other current assets	462	1,297
Total current assets	16,063	26,350
Property and equipment, net	1,790	2,101
Ownership interests and advances	50,398	77,129
Other assets	784	1,997
Total Assets	69,035	107,577
Current Liabilities:
Accounts payable	56	39
Accrued compensation and benefits	2,677	1,364
Accrued expenses and other current liabilities	410	627
Lease liability - current	327	399
Total current liabilities	3,470	2,429
Other long-term liabilities	637	1,027
Lease liability - non-current	2,053	2,380
Total Liabilities	6,160	5,836
Commitments and contingencies (Note 12)
Equity:
Preferred stock, $0.10 par value; 1,000 shares authorized	0	0
Common stock, $0.10 par value; 83,333 shares authorized; 21,573 issued at December 31, 2020 and 2019, respectively	2,157	2,157
Additional paid-in capital	807,582	810,856
Treasury stock, at cost; 688 and 930 shares at December 31, 2020 and 2019, respectively	(10,200)	(14,024)
Accumulated deficit	(736,639)	(697,223)
Accumulated other comprehensive loss	(25)	(25)
Total Equity	62,875	101,741
Total Liabilities and Equity	$ 69,035	$ 107,577

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares shares in Thousands	Dec. 31, 2020	Dec. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, shares authorized (in shares)	1,000	1,000
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, shares authorized (in shares)	83,333	83,333
Common stock, shares issued (in shares)	21,573	21,573
Treasury stock, shares (in shares)	688	930

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
General and administrative expense	$ 9,466	$ 9,982
Operating loss	(9,466)	(9,982)
Other income (loss), net	(7,708)	12,255
Interest income	261	2,044
Interest expense	0	(14,023)
Equity income (loss), net	(20,702)	64,267
Net income (loss) before income taxes	(37,615)	54,561
Income tax benefit (expense)	0	0
Net income (loss)	$ (37,615)	$ 54,561
Net income (loss) per share:
Basic (in dollars per share)	$ (1.81)	$ 2.64
Diluted (in dollars per share)	$ (1.81)	$ 2.64
Weighted average shares used in computing net income (loss) per share:
Basic (in shares)	20,751	20,636
Diluted (in shares)	20,751	20,636

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Net income (loss)	$ (37,615)	$ 54,561
Other comprehensive (loss) income:
Share of other comprehensive (loss) of equity method investments	0	(31)
Reclassification adjustment for sale of equity method investments	0	6
Total comprehensive income (loss)	$ (37,615)	$ 54,536

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Total
Balance at Dec. 31, 2018	$ (731,105)	$ 0	$ 2,157	$ 810,928	$ (15,001)	$ 66,979
Balance (in shares) at Dec. 31, 2018			21,573		914
Net income (loss)	54,561	0	$ 0	0	$ 0	54,561
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net	0	0	$ 0	(1,213)	$ 977	(236)
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares)			0		16
Stock-based compensation	0	0	$ 0	1,141	$ 0	1,141
Other comprehensive income (loss)	0	(25)	0	0	0	(25)
Dividends paid	(20,679)	0	0	0	0	(20,679)
Balance at Dec. 31, 2019	(697,223)	(25)	$ 2,157	810,856	$ (14,024)	101,741
Balance (in shares) at Dec. 31, 2019			21,573		930
Net income (loss)	(37,615)	0	$ 0	0	$ 0	(37,615)
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net	0	0	$ 0	(3,864)	$ 3,824	(40)
Restricted stock awards, forfeitures and shares repurchased for tax withholdings, net (in shares)			0		(242)
Stock-based compensation	0	0	$ 0	590	$ 0	590
Change in accounting at ownership interests	(1,801)	0	0	0	0	(1,801)
Balance at Dec. 31, 2020	$ (736,639)	$ (25)	$ 2,157	$ 807,582	$ (10,200)	$ 62,875
Balance (in shares) at Dec. 31, 2020			21,573		688

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash Flows from Operating Activities:
Net income (loss)	$ (37,615)	$ 54,561
Adjustments to reconcile to net cash used in operating activities:
Depreciation	0	808
Amortization of debt discount	0	3,454
Amortization of right of use asset	311	260
Equity (income) loss, net	9,420	(67,232)
Impairments of ownership interests and advances	20,039	3,012
Income from change in fair value of derivative	0	(5,060)
Gain from observable price changes	(1,224)	(4,526)
Other, net	175	(2,315)
Stock-based compensation, including liability classified awards	965	1,237
Changes in assets and liabilities:
Prepaid expenses and other current assets	(137)	(823)
Accounts payable, accrued expenses, and other current liabilities	(77)	(3,346)
Net cash used in operating activities	(8,143)	(19,970)
Cash Flows from Investing Activities:
Acquisitions of ownership interests	(7,534)	(11,640)
Proceeds from sales and distributions from ownership interests	7,903	104,302
Advances and loans to ownership interests	(1,638)	(5,055)
Repayment of advances and loans from ownership interests	0	750
Purchase of marketable securities	0	(57,243)
Proceeds, from sales and maturities in marketable securities	0	95,189
Net cash (used in) provided by investing activities	(1,269)	126,303
Cash Flows from Financing Activities:
Payment of dividend	0	(20,679)
Repayments on credit facility	0	(68,568)
Tax withholdings related to equity-based awards	(40)	(236)
Net cash used in financing activities	(40)	(89,483)
Net change in cash, cash equivalents and restricted cash	(9,452)	16,850
Cash, cash equivalents and restricted cash equivalents at beginning of period	25,053	8,203
Cash, cash equivalents and restricted cash at end of period	$ 15,601	$ 25,053

Note 1 - General

Note 1 - General	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Liquidity And Capital Resources As of December 31, 2020 In January 2018, not The Company believes that its cash and cash equivalents at December 31, 2020 one Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Safeguard and all of its subsidiaries in which a controlling financial interest is maintained. All intercompany accounts and transactions are eliminated in consolidation. Principles of Accounting for Ownership Interests in Companies The Company accounts for its ownership interests using one In addition to holding voting and non-voting equity and debt securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in the Ownership interests and advances on the Consolidated Balance Sheets. Equity Method. not not 20% 50% not one When the Company’s carrying value in an equity method company is reduced to zero, the Company records no not not Other Method. not not Accounting Estimates The preparation of the Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect amounts reported in the financial statements and accompanying notes. Actual results may Certain amounts recorded to reflect the Company’s share of income or losses for companies accounted for under the equity method are based on unaudited results of operations of those companies and may It is reasonably possible that the Company’s accounting estimates with respect to the ultimate recoverability of the carrying value of the Company’s ownership interests and advances could change in the near term and that the effect of such changes on the consolidated financial statements could be material. At December 31, 2020 not no not not Cash and Cash Equivalents and Marketable Securities The Company considers all highly liquid instruments with an original maturity of 90 one not not Restricted Cash Restricted cash equivalents represents cash required to be set aside by a contractual agreement as a shareholder representative. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets: December 31, 2020 December 31, 2019 (In thousands) Cash and cash equivalents $ 15,601 $ 25,028 Restricted cash — 25 Total cash, cash equivalents and restricted cash $ 15,601 $ 25,053 Financial Instruments The Company’s financial instruments (principally cash and cash equivalents, marketable securities, accounts receivable, notes receivable, accounts payable and accrued expenses) are carried at cost, which approximates fair value due to the short-term maturity of these instruments. Property and Equipment Property and equipment represents right-of-use assets resulting from the adoption of Accounting Standards Update ("ASU") No. 2016 02, Leases April 2026) Lease liability The initial lease liability represents the present value of the fixed escalating lease payments through April 2026 No. 2016 02, Leases no December 31, 2020 2019 December 31, 2020 2019 In March 2019, April 2026, In April 2019, June 2019. 2020. not A summary of the Company's operating lease cash flows at December 31, 2020 Operating lease payments Expected sublease receipts (In thousands) 2021 $ 595 $ 525 2022 601 540 2023 607 556 2024 613 573 2025 619 590 2026 208 199 Thereafter — — Total future minimum lease payments 3,243 2,983 Less imputed interest (863 ) Total operating lease liabilities $ 2,380 Valuation of Credit Facility repayment feature The fair value of the Credit Facility repayment feature (a Level 3 July 2019 Impairment of Ownership Interests and Advances On a periodic basis, but no not Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value. The estimated fair value of privately held companies is generally determined based on the value at which independent third Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations. The reduced cost basis of a previously impaired company accounted for using the Equity method are not Income Taxes The Company accounts for income taxes under the asset and liability method whereby deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company measures deferred tax assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be recovered or settled. The Company recognizes the effect on deferred tax assets and liabilities of a change in tax rates in income in the period of the enactment date. The Company provides a valuation allowance against the net deferred tax asset for amounts which are not not Net Income (Loss) Per Share The Company computes net income (loss) per share using the weighted average number of common shares outstanding during each year. The Company includes in diluted net income (loss) per share common stock equivalents (unless anti-dilutive) which would arise from the exercise of stock options and conversion of other convertible securities and adjusted, if applicable, for the effect on net income (loss) of such transactions. Diluted net income (loss) per share calculations adjust net income (loss) for the dilutive effect of common stock equivalents and convertible securities issued by the Company’s consolidated or equity method companies. Segment Information The Company operates as one Recently Adopted Accounting Pronouncements In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09" 2014 09 December 15, 2017 December 15, 2018 December 15, 2019 June 3, 2020 2020 05, 606 not 2019 June 3, 2020, January 1, 2020. As the new standard superseded most existing revenue guidance, it impacted revenue and cost recognition for companies in which we hold an ownership interest. Any change in revenue or cost recognition for companies in which we hold an ownership interest could affect the Company's recognition of its share of the results of its equity method companies. On July 20, 2017, not not December 31, 2019, first 2019 For our ownership interests that have adopted ASU 2014 09, 2020 one December 31, 2020 2019 2014 09. 2014 09 not

Note 2 - Ownership Interests an

Note 2 - Ownership Interests and Advances	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	2. The following summarizes the carrying value of the Company’s ownership interests and advances. December 31, 2020 December 31, 2019 (In thousands) Equity Method: Companies $ 27,550 $ 34,271 Private equity funds 271 271 27,821 34,542 Other Method: Companies 19,683 27,031 Private equity funds 268 453 19,951 27,484 Advances to companies (equity method) 2,626 15,103 $ 50,398 $ 77,129 In September 2020, During the year ended December 31, 2020, December 31, 2020, b8ta 19 third 3 During the year ended December 31, 2020, December 31, 2020, During 2019, August 2019 In January 2019, 2020 In January 2019, not 2019 In May 2019, may May 2020. During 2019, During 2019, Summarized Financial Information The following table provides summarized financial information for ownership interests accounted for under the equity method for the periods presented and has been compiled from respective company financial statements, reflect certain historical adjustments, and are reported on a one not As of December 31, 2020 2019 (In thousands) Balance Sheets: Current assets $ 104,024 $ 91,968 Non-current assets 26,352 26,231 Total assets $ 130,376 $ 118,199 Current liabilities $ 72,972 $ 80,783 Non-current liabilities 105,506 87,081 Shareholders’ deficit (48,102 ) (49,665 ) Total liabilities and shareholders’ deficit $ 130,376 $ 118,199 Number of equity method ownership interests 12 13 Year Ended December 31, 2020 2019 (In thousands) Results of Operations: Revenue $ 153,875 $ 145,632 Gross profit $ 92,039 $ 78,465 Net loss $ (82,216 ) $ (127,007 ) As of December 31, 2020

Note 3 - Acquisitions of Owners

Note 3 - Acquisitions of Ownership Interests	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Cost and Equity Method Investments Disclosure [Text Block]	3. 2020 The Company deployed an additional $2.5 million to Aktana, Inc. during the three September 30, 2020. six June 30, 2020, first 2020 second The Company deployed an additional $1.0 million to meQuilibrium during the three March 31, 2020. The Company funded an additional $0.7 million of convertible loans to Trice Medical, Inc. during the six June 30, 2020. The Company deployed an aggregate of $0.2 million to Clutch Holdings during the three June 30, 2020. The Company funded an additional $0.2 million of convertible loans to QuanticMind during the three March 31, 2020. 2 2020 16 2021. The Company funded an aggregate of $0.1 million of convertible loans to WebLinc, Inc. during the three March 31, 2020. 2 2020 16 2021. 2019 The Company deployed an additional $5.0 million to Syapse, Inc. The Company deployed an additional $2.0 million to Moxe Health Corporation, including $0.3 million that was funded initially as a convertible loan. The Company had previously deployed $5.5 million in Moxe Health. The Company deployed an additional $1.5 million to Aktana, Inc. The Company deployed an additional $1.5 million to meQuilibrium. The Company deployed an additional $1.5 million to Zipnosis, Inc. The Company had previously deployed $8.5 million in Zipnosis. Zipnosis provides health systems with a white-labeled, fully integrated virtual care platform. The Company deployed an aggregate of $0.4 million to Clutch Holdings. The Company funded an additional $2.0 million of convertible loans to Sonobi, Inc. The Company had previously deployed $11.4 million in Sonobi. Sonobi is an advertising technology developer that was acquired during 2020. 2 2020. The Company funded an aggregate of $1.1 million of convertible loans to WebLinc, Inc. See Note 2 2020 16 2021. The Company funded an aggregate of $1.0 million of convertible loans to NovaSom, Inc. The Company had previously deployed an aggregate of $26.4 million in NovaSom. See Note 2 second 2019. The Company funded an additional $0.6 million of convertible loans to QuanticMind. See Note 2 2020 16 2021.

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4. The Company categorizes its financial instruments into a three 1 3 Cash equivalents approximate fair value due to their short term nature. The Company did not 2 3 December 31, 2020 2019

Note 5 - Credit Facility and Co

Note 5 - Credit Facility and Convertible Debentures	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Long-term Debt [Text Block]	5. Credit Facility The Company's credit facility was with HPS Investment Partners, LLC (“Lender”), and was amended in May 2018 ( May 11, 2020 two three 2%; 0.5%; 1%; The terms of the Credit Facility included a requirement that if the aggregate amount of the Company’s qualified cash at any quarter end date exceeded $50.0 million, the Company would be required to prepay outstanding principal amounts under the Credit Facility, plus any applicable interest and prepayment fees, in an amount equal to such excess. Based on this requirement, the Company made a principal payment of $24.0 million and a make-whole interest payment of $2.9 million on April 15, 2019 March 31, 2019. July 2019. The Company was subject to certain debt covenants under the Credit Facility including maintaining a specified level of liquidity threshold, maintaining an appraised value of ownership interests, limiting deployments to our remaining ownership interests, limiting certain expenses, and restricting any repurchases of outstanding common stock or issuing dividends until such time as the Credit Facility was repaid in full. The Company was in compliance with all applicable covenants. The Credit Facility required prepayments of outstanding principal and interest amounts when the Company’s qualified cash at any quarter end date exceeded $50.0 million. This provision in the Credit Facility was an embedded derivative that was accounted for separately from the Credit Facility. A liability of $0.5 million was recorded on the 2018 2019, The Company recorded interest expense under the Credit Facility of $14.0 million for the year ended December 31, 2019. December 31, 2019.

Note 6 - Equity

Note 6 - Equity	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	6. In July 2015, December 31, 2020 2019 not In February 2018, 2018 382 five 382 50 five three 382, one March 2, 2018. not not no February 19, 2021. On November 7, 2019, December 30, 2019 December 23, 2019,

Note 7 - Stock-Based Compensati

Note 7 - Stock-Based Compensation	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	7. Equity Compensation Plans The 2014 2020 2019 no first December 31, 2020 2014 Classification of Stock-Based Compensation Expense Stock-based compensation expense was recognized in the Consolidated Statements of Operations as follows: Year Ended December 31, 2020 2019 (In thousands) General and administrative expense $ 965 $ 1,237 $ 965 $ 1,237 At December 31, 2020 1 2 Performance-based awards entitle participants to vest in a number of awards determined by achievement by the Company of target capital returns based on net cash proceeds received by the Company upon the sale, merger or other exit transaction of certain identified companies. Vesting may not December 31, 2020 2019 December 31, 2020 2019 December 31, 2020 2019 December 31, 2020 2019 December 31, 2020 Service-based awards generally vest over four eight December 31, 2020 2019 December 31, 2020 2019 There were no options granted during 2020 2019 Stock-based compensation expense of $1.0 million was recognized during the year ended December 31, 2020 2020 December 31, 2020 2019, December 31, 2019 Option activity of the Company is summarized below: Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value (In thousands) (In years) (In thousands) Outstanding at January 1, 2019 410 14.66 Options granted — — Options exercised — — Options canceled/forfeited (231 ) 14.19 Outstanding at December 31, 2019 179 15.27 Options granted — — Options exercised — — Options canceled/forfeited (134 ) 14.36 Outstanding at December 31, 2020 45 14.20 2.29 $ — Options exercisable at December 31, 2020 22 14.48 3.08 — Shares available for future grant 2,515 At December 31, 2020 December 31, 2020 Performance-based stock units vest based on achievement by the Company of target capital returns based on net cash proceeds received by the Company on the sale, merger or other exit transaction of certain identified companies, as described above related to performance-based awards. During 2020, 2021 one one none December 31, 2020. December 31, 2020 2019 December 31, 2020 2019 December 31, 2020 2019 2016 2015 December 31, 2020 During the years ended December 31, 2020 2019 two four 65 December 31, 2020 2019 During the years ended December 31, 2020 2019 one 65. one one Total compensation expense for deferred stock units, performance-based stock units and restricted stock was $0.5 million and $1.2 million, for the years ended December 31, 2020 2019 December 31, 2020 December 31, 2020 2019 Deferred stock unit, performance-based stock unit and restricted stock activity are summarized below: Shares Weighted Average Grant Date Fair Value (In thousands) Unvested at January 1, 2019 777 $ 14.08 Granted 31 12.12 Vested (107 ) 11.79 Forfeited (414 ) 14.28 Unvested at December 31, 2019 287 14.44 Granted 313 5.89 Vested (174 ) 7.77 Forfeited (139 ) 15.24 Unvested at December 31, 2020 287 8.78

Note 8 - Employee Benefit Plan

Note 8 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	8. n The Company maintains a qualified 401 first December 31, 2020 2019

Note 9 - Income Taxes

Note 9 - Income Taxes	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	9. The federal and state provision (benefit) for income taxes was $0.0 million for the years ended December 31, 2020 2019 The total income tax provision (benefit) differed from the amounts computed by applying the U.S. federal income tax rate of 21.0% for the years ended December 31, 2020 2019 Year Ended December 31, 2020 2019 Statutory tax (benefit) expense 21.0 % 21.0 % Increase (decrease) in taxes resulting from: Nondeductible expenses (4.1 ) 0.4 Valuation allowance (16.9 ) (21.4 ) 0.0 % 0.0 % The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets were as follows: As of December 31, 2020 2019 (In thousands) Deferred tax asset: Carrying values of ownership interests and other holdings $ 38,361 $ 32,760 Tax loss and credit carryforwards 76,023 70,914 Disallowed interest carryforwards 7,292 7,292 Accrued expenses 497 213 Stock-based compensation 302 432 Other 482 604 122,957 112,215 Valuation allowance (122,957 ) (112,215 ) Net deferred tax asset $ — $ — As of December 31, 2020 Total (In thousands) 2021 $ 3,728 2022 48,848 2023 52,512 2024 50,140 2025 and thereafter 170,189 $ 325,417 In assessing the recoverability of deferred tax assets, the Company considers whether it is more likely than not not not may not The Company recognizes in its Consolidated Financial Statements the impact of a tax position if that position is more likely than not The Company does not twelve There were no changes in the Company’s uncertain tax positions for the years ended December 31, 2020 2019 The Company files income tax returns in the U.S. federal jurisdiction, and various state jurisdictions. Tax years 2015 December 31, 2020

Note 10 - Net Income (Loss) Per

Note 10 - Net Income (Loss) Per Share	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	10. The calculations of net income (loss) per share were: Year Ended December 31, 2020 2019 (In thousands, except per share data) Basic: Net income (loss) $ (37,615 ) $ 54,561 Weighted average common shares outstanding 20,751 20,636 Net income (loss) per share $ (1.81 ) $ 2.64 Diluted: Net income (loss) $ (37,615 ) $ 54,561 Weighted average common shares outstanding 20,751 20,636 Net income (loss) per share $ (1.81 ) $ 2.64 Basic and diluted average common shares outstanding for purposes of computing net income (loss) per share includes outstanding common shares and vested deferred stock units (DSUs). If an equity method company has dilutive stock options, unvested restricted stock, DSUs, or warrants, diluted net income (loss) per share is computed by first Diluted income (loss) per share for the years ended December 31, 2020 2019 not • At December 31, 2020 2019 • At December 31, 2020 2019 • For the year ended December 31, 2019 2019

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	11. In the normal course of business, the Company’s officers and employees hold board positions with companies in which the Company has a direct or indirect ownership interest.

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	12. The Company and the companies in which it holds ownership interests are involved in various claims and legal actions arising in the ordinary course of business. In the current opinion of the Company, the ultimate disposition of these matters will not no one The Company had outstanding guarantees of $3.8 million at December 31, 2020 one In October 2001, 2019. The Company has agreements with certain employees that provide for severance payments to the employee in the event the employee is terminated without cause or an employee terminates his employment for “good reason.” The maximum aggregate exposure under severance agreements for remaining employees is approximately $2.3 million at December 31, 2020 In 2018, February 2019 June 2020, January 2018. June 2020 first may first first no second 60 December 31, 2020 In June 2011, March 2012, July 2015 one 2014 one

Note 13 - Supplemental Cash Flo

Note 13 - Supplemental Cash Flow Information	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	13. During the years ended December 31, 2020 2019 December 31, 2020 2019 December 31, 2020 2019

Note 14 - Segment Reporting

Note 14 - Segment Reporting	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	14. The Company operates as one operating segment based upon the similar nature of its technology-driven companies, the functional alignment of the organizational structure, and the reports that are regularly reviewed by the chief operating decision maker for the purpose of assessing performance and allocating resources. As of December 31, 2020 2019 Certain of the Company’s ownership interests as of December 31, 2020 2019 Safeguard Primary Ownership as of December 31, Company Name 2020 2019 Accounting Method Aktana, Inc. 15.1 % 17.8 % Equity Clutch Holdings, Inc. 42.3 % 41.2 % Equity Flashtalking, Inc. 13.4 % 10.1 % Other InfoBionic, Inc. 25.2 % 25.2 % Equity Lumesis, Inc. 43.4 % 43.5 % Equity MediaMath, Inc. 13.3 % 13.3 % Other meQuilibrium 32.0 % 32.7 % Equity Moxe Health Corporation 27.6 % 29.9 % Equity Prognos Health Inc. 28.5 % 28.7 % Equity QuanticMind, Inc. * 24.2 % 24.2 % Equity Syapse, Inc. 18.9 % 20.0 % Equity T-REX Group, Inc. 13.5 % 13.7 % Other Trice Medical, Inc. 16.6 % 16.6 % Equity WebLinc, Inc. * 39.9 % 38.5 % Equity Zipnosis, Inc 37.2 % 37.7 % Equity * These entities were sold subsequent to December 31, 2020. 16 As of December 31, 2020 2019

Note 15 - Selected Quarterly Fi

Note 15 - Selected Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Quarterly Financial Information [Text Block]	15. Three Months Ended March 31 June 30 September 30 (b) December 31 (b) (In thousands, except per share data) 2020: General and administrative expense $ 3,532 $ 2,028 $ 2,275 $ 1,631 Operating loss (3,532 ) (2,028 ) (2,275 ) (1,631 ) Other income (loss), net (3,567 ) (2,658 ) (820 ) (663 ) Interest income 105 52 52 52 Equity income (loss), net (9,014 ) (5,277 ) (1,300 ) (5,111 ) Net loss before income taxes (16,008 ) (9,911 ) (4,343 ) (7,353 ) Income tax benefit (expense) — — — — Net loss $ (16,008 ) $ (9,911 ) $ (4,343 ) $ (7,353 ) Net loss per share (a) Basic $ (0.77 ) $ (0.48 ) $ (0.21 ) $ (0.35 ) Diluted $ (0.77 ) $ (0.48 ) $ (0.21 ) $ (0.35 ) 2019: General and administrative expense $ 3,057 $ 2,603 $ 2,262 $ 2,060 Operating loss (3,057 ) (2,603 ) (2,262 ) (2,060 ) Other income (loss), net (1,885 ) 3,118 8,777 2,245 Interest income 873 763 234 174 Interest expense (2,535 ) (5,682 ) (5,806 ) — Equity income (loss), net 28,267 40,497 (3,440 ) (1,057 ) Net income (loss) before income taxes 21,663 36,093 (2,497 ) (698 ) Income tax benefit (expense) — — — — Net income (loss) $ 21,663 $ 36,093 $ (2,497 ) $ (698 ) Net income (loss) per share (a) Basic $ 1.05 $ 1.75 $ (0.12 ) $ (0.03 ) Diluted $ 1.05 $ 1.75 $ (0.12 ) $ (0.03 ) (a) Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not may not (b) The three December 31, 2019 three September 30, 2019. no

Note 16 - Subsequent Events

Note 16 - Subsequent Events	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	16. In January 2021, may February 2021, During February 2021,

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of Safeguard and all of its subsidiaries in which a controlling financial interest is maintained. All intercompany accounts and transactions are eliminated in consolidation.
Investment, Policy [Policy Text Block]	Principles of Accounting for Ownership Interests in Companies The Company accounts for its ownership interests using one In addition to holding voting and non-voting equity and debt securities, the Company also periodically makes advances to its companies in the form of promissory notes which are included in the Ownership interests and advances on the Consolidated Balance Sheets. Equity Method. not not 20% 50% not one When the Company’s carrying value in an equity method company is reduced to zero, the Company records no not not Other Method. not not
Use of Estimates, Policy [Policy Text Block]	Accounting Estimates The preparation of the Consolidated Financial Statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect amounts reported in the financial statements and accompanying notes. Actual results may Certain amounts recorded to reflect the Company’s share of income or losses for companies accounted for under the equity method are based on unaudited results of operations of those companies and may It is reasonably possible that the Company’s accounting estimates with respect to the ultimate recoverability of the carrying value of the Company’s ownership interests and advances could change in the near term and that the effect of such changes on the consolidated financial statements could be material. At December 31, 2020 not no not not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents and Marketable Securities The Company considers all highly liquid instruments with an original maturity of 90 one not not
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash Restricted cash equivalents represents cash required to be set aside by a contractual agreement as a shareholder representative. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets: December 31, 2020 December 31, 2019 (In thousands) Cash and cash equivalents $ 15,601 $ 25,028 Restricted cash — 25 Total cash, cash equivalents and restricted cash $ 15,601 $ 25,053
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments The Company’s financial instruments (principally cash and cash equivalents, marketable securities, accounts receivable, notes receivable, accounts payable and accrued expenses) are carried at cost, which approximates fair value due to the short-term maturity of these instruments.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment represents right-of-use assets resulting from the adoption of Accounting Standards Update ("ASU") No. 2016 02, Leases April 2026)
Lessee, Leases [Policy Text Block]	Lease liability The initial lease liability represents the present value of the fixed escalating lease payments through April 2026 No. 2016 02, Leases no December 31, 2020 2019 December 31, 2020 2019 In March 2019, April 2026, In April 2019, June 2019. 2020. not A summary of the Company's operating lease cash flows at December 31, 2020 Operating lease payments Expected sublease receipts (In thousands) 2021 $ 595 $ 525 2022 601 540 2023 607 556 2024 613 573 2025 619 590 2026 208 199 Thereafter — — Total future minimum lease payments 3,243 2,983 Less imputed interest (863 ) Total operating lease liabilities $ 2,380
Valuation of Credit Facility Repayment Feature, Policy [Policy Text Block]	Valuation of Credit Facility repayment feature The fair value of the Credit Facility repayment feature (a Level 3 July 2019
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Ownership Interests and Advances On a periodic basis, but no not Management then determines whether there has been an other than temporary decline in the value of its ownership interest in the company. Impairment is measured as the amount by which the carrying value of an asset exceeds its estimated fair value. The estimated fair value of privately held companies is generally determined based on the value at which independent third Impairment charges related to equity method companies are included in Equity income (loss), net in the Consolidated Statements of Operations. Impairment charges related to non-equity method companies and funds are included in Other income (loss), net in the Consolidated Statements of Operations. The reduced cost basis of a previously impaired company accounted for using the Equity method are not
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method whereby deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company measures deferred tax assets and liabilities using enacted tax rates in effect for the year in which the temporary differences are expected to be recovered or settled. The Company recognizes the effect on deferred tax assets and liabilities of a change in tax rates in income in the period of the enactment date. The Company provides a valuation allowance against the net deferred tax asset for amounts which are not not
Earnings Per Share, Policy [Policy Text Block]	Net Income (Loss) Per Share The Company computes net income (loss) per share using the weighted average number of common shares outstanding during each year. The Company includes in diluted net income (loss) per share common stock equivalents (unless anti-dilutive) which would arise from the exercise of stock options and conversion of other convertible securities and adjusted, if applicable, for the effect on net income (loss) of such transactions. Diluted net income (loss) per share calculations adjust net income (loss) for the dilutive effect of common stock equivalents and convertible securities issued by the Company’s consolidated or equity method companies.
Segment Reporting, Policy [Policy Text Block]	Segment Information The Company operates as one
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09" 2014 09 December 15, 2017 December 15, 2018 December 15, 2019 June 3, 2020 2020 05, 606 not 2019 June 3, 2020, January 1, 2020. As the new standard superseded most existing revenue guidance, it impacted revenue and cost recognition for companies in which we hold an ownership interest. Any change in revenue or cost recognition for companies in which we hold an ownership interest could affect the Company's recognition of its share of the results of its equity method companies. On July 20, 2017, not not December 31, 2019, first 2019 For our ownership interests that have adopted ASU 2014 09, 2020 one December 31, 2020 2019 2014 09. 2014 09 not

Note 1 - General (Tables)

Note 1 - General (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Restrictions on Cash and Cash Equivalents [Table Text Block]	December 31, 2020 December 31, 2019 (In thousands) Cash and cash equivalents $ 15,601 $ 25,028 Restricted cash — 25 Total cash, cash equivalents and restricted cash $ 15,601 $ 25,053
Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]	Operating lease payments Expected sublease receipts (In thousands) 2021 $ 595 $ 525 2022 601 540 2023 607 556 2024 613 573 2025 619 590 2026 208 199 Thereafter — — Total future minimum lease payments 3,243 2,983 Less imputed interest (863 ) Total operating lease liabilities $ 2,380

Note 2 - Ownership Interests _2

Note 2 - Ownership Interests and Advances (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Investments in and Advances to Affiliates, Schedule of Investments [Table Text Block]	December 31, 2020 December 31, 2019 (In thousands) Equity Method: Companies $ 27,550 $ 34,271 Private equity funds 271 271 27,821 34,542 Other Method: Companies 19,683 27,031 Private equity funds 268 453 19,951 27,484 Advances to companies (equity method) 2,626 15,103 $ 50,398 $ 77,129
Equity Method Investment Partner Company Results Of Operation [Table Text Block]	As of December 31, 2020 2019 (In thousands) Balance Sheets: Current assets $ 104,024 $ 91,968 Non-current assets 26,352 26,231 Total assets $ 130,376 $ 118,199 Current liabilities $ 72,972 $ 80,783 Non-current liabilities 105,506 87,081 Shareholders’ deficit (48,102 ) (49,665 ) Total liabilities and shareholders’ deficit $ 130,376 $ 118,199 Number of equity method ownership interests 12 13
Equity Method Investments [Table Text Block]	Year Ended December 31, 2020 2019 (In thousands) Results of Operations: Revenue $ 153,875 $ 145,632 Gross profit $ 92,039 $ 78,465 Net loss $ (82,216 ) $ (127,007 )

Note 7 - Stock-Based Compensa_2

Note 7 - Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Share-based Payment Arrangement, Activity [Table Text Block]	Year Ended December 31, 2020 2019 (In thousands) General and administrative expense $ 965 $ 1,237 $ 965 $ 1,237
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value (In thousands) (In years) (In thousands) Outstanding at January 1, 2019 410 14.66 Options granted — — Options exercised — — Options canceled/forfeited (231 ) 14.19 Outstanding at December 31, 2019 179 15.27 Options granted — — Options exercised — — Options canceled/forfeited (134 ) 14.36 Outstanding at December 31, 2020 45 14.20 2.29 $ — Options exercisable at December 31, 2020 22 14.48 3.08 — Shares available for future grant 2,515
Schedule Of Activity For Restricted Stock Units Deferred Stock Units And Performance Units [Table Text Block]	Shares Weighted Average Grant Date Fair Value (In thousands) Unvested at January 1, 2019 777 $ 14.08 Granted 31 12.12 Vested (107 ) 11.79 Forfeited (414 ) 14.28 Unvested at December 31, 2019 287 14.44 Granted 313 5.89 Vested (174 ) 7.77 Forfeited (139 ) 15.24 Unvested at December 31, 2020 287 8.78

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2020 2019 Statutory tax (benefit) expense 21.0 % 21.0 % Increase (decrease) in taxes resulting from: Nondeductible expenses (4.1 ) 0.4 Valuation allowance (16.9 ) (21.4 ) 0.0 % 0.0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2020 2019 (In thousands) Deferred tax asset: Carrying values of ownership interests and other holdings $ 38,361 $ 32,760 Tax loss and credit carryforwards 76,023 70,914 Disallowed interest carryforwards 7,292 7,292 Accrued expenses 497 213 Stock-based compensation 302 432 Other 482 604 122,957 112,215 Valuation allowance (122,957 ) (112,215 ) Net deferred tax asset $ — $ —
Summary of Operating Loss Carryforwards [Table Text Block]	Total (In thousands) 2021 $ 3,728 2022 48,848 2023 52,512 2024 50,140 2025 and thereafter 170,189 $ 325,417

Note 10 - Net Income (Loss) P_2

Note 10 - Net Income (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended December 31, 2020 2019 (In thousands, except per share data) Basic: Net income (loss) $ (37,615 ) $ 54,561 Weighted average common shares outstanding 20,751 20,636 Net income (loss) per share $ (1.81 ) $ 2.64 Diluted: Net income (loss) $ (37,615 ) $ 54,561 Weighted average common shares outstanding 20,751 20,636 Net income (loss) per share $ (1.81 ) $ 2.64

Note 14 - Segment Reporting (Ta

Note 14 - Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Partner Company Ownership Interest [Table Text Block]	Safeguard Primary Ownership as of December 31, Company Name 2020 2019 Accounting Method Aktana, Inc. 15.1 % 17.8 % Equity Clutch Holdings, Inc. 42.3 % 41.2 % Equity Flashtalking, Inc. 13.4 % 10.1 % Other InfoBionic, Inc. 25.2 % 25.2 % Equity Lumesis, Inc. 43.4 % 43.5 % Equity MediaMath, Inc. 13.3 % 13.3 % Other meQuilibrium 32.0 % 32.7 % Equity Moxe Health Corporation 27.6 % 29.9 % Equity Prognos Health Inc. 28.5 % 28.7 % Equity QuanticMind, Inc. * 24.2 % 24.2 % Equity Syapse, Inc. 18.9 % 20.0 % Equity T-REX Group, Inc. 13.5 % 13.7 % Other Trice Medical, Inc. 16.6 % 16.6 % Equity WebLinc, Inc. * 39.9 % 38.5 % Equity Zipnosis, Inc 37.2 % 37.7 % Equity

Note 15 - Selected Quarterly _2

Note 15 - Selected Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Quarterly Financial Information [Table Text Block]	Three Months Ended March 31 June 30 September 30 (b) December 31 (b) (In thousands, except per share data) 2020: General and administrative expense $ 3,532 $ 2,028 $ 2,275 $ 1,631 Operating loss (3,532 ) (2,028 ) (2,275 ) (1,631 ) Other income (loss), net (3,567 ) (2,658 ) (820 ) (663 ) Interest income 105 52 52 52 Equity income (loss), net (9,014 ) (5,277 ) (1,300 ) (5,111 ) Net loss before income taxes (16,008 ) (9,911 ) (4,343 ) (7,353 ) Income tax benefit (expense) — — — — Net loss $ (16,008 ) $ (9,911 ) $ (4,343 ) $ (7,353 ) Net loss per share (a) Basic $ (0.77 ) $ (0.48 ) $ (0.21 ) $ (0.35 ) Diluted $ (0.77 ) $ (0.48 ) $ (0.21 ) $ (0.35 ) 2019: General and administrative expense $ 3,057 $ 2,603 $ 2,262 $ 2,060 Operating loss (3,057 ) (2,603 ) (2,262 ) (2,060 ) Other income (loss), net (1,885 ) 3,118 8,777 2,245 Interest income 873 763 234 174 Interest expense (2,535 ) (5,682 ) (5,806 ) — Equity income (loss), net 28,267 40,497 (3,440 ) (1,057 ) Net income (loss) before income taxes 21,663 36,093 (2,497 ) (698 ) Income tax benefit (expense) — — — — Net income (loss) $ 21,663 $ 36,093 $ (2,497 ) $ (698 ) Net income (loss) per share (a) Basic $ 1.05 $ 1.75 $ (0.12 ) $ (0.03 ) Diluted $ 1.05 $ 1.75 $ (0.12 ) $ (0.03 )

Note 1 - General (Details Textu

Note 1 - General (Details Textual) - USD ($) $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2020		Sep. 30, 2020	[1]	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019		Sep. 30, 2019	[1]	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Jan. 01, 2020	Apr. 30, 2019	Dec. 31, 2018
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 15,601						$ 25,028						$ 15,601	$ 25,028
Lessee, Operating Lease, Discount Rate	12.00%												12.00%
Operating Lease, Cost													$ 500	500
Operating Lease, Payments													600	600
Lessor, Operating Lease, Term of Contract (Month)																18 months
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance	$ 62,875						101,741						62,875	101,741			$ 66,979
Operating Income (Loss), Total	(1,631)	[1]	$ (2,275)		$ (2,028)	$ (3,532)	(2,060)	[1]	$ (2,262)		$ (2,603)	$ (3,057)	(9,466)	(9,982)
Retained Earnings [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance	(736,639)						$ (697,223)						(736,639)	$ (697,223)			$ (731,105)
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2014-09 [Member]
Operating Income (Loss), Total													1,800
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance															$ 1,800
Cumulative Effect, Period of Adoption, Adjustment [Member] | Accounting Standards Update 2014-09 [Member] | Noncontrolling Interest [Member]
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance															$ (1,800)
Revolving Credit Facility [Member]
Debt Instrument, Debt Covenants, Cash and Cash Equivalent Threshold	$ 50,000												$ 50,000
[1]	The three months ended December 31, 2019 includes equity income of $1.4 million related to an equity method investment that should have been recorded during the three months ended September 30, 2019. There was no impact on the full year results.

Note 1 - General - Schedule of

Note 1 - General - Schedule of Restrictions on Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 15,601	$ 25,028
Restricted cash	0	25
Total cash, cash equivalents and restricted cash	$ 15,601	$ 25,053	$ 8,203

Note 1 - General - Schedule o_2

Note 1 - General - Schedule of Leases (Details) $ in Thousands	Dec. 31, 2020USD ($)
2021, operating lease payments	$ 595
2021, expected sublease receipts	525
2022, operating lease payments	601
2022, expected sublease receipts	540
2023, operating lease payments	607
2023, expected sublease receipts	556
2024, operating lease payments	613
2024, expected sublease receipts	573
2025, operating lease payments	619
2025, expected sublease receipts	590
2026, operating lease payments	208
2026, expected sublease receipts	199
Thereafter, operating lease payments	0
Thereafter, expected sublease receipts	0
Total future minimum lease payments, operating lease payments	3,243
Total future minimum lease payments, expected sublease receipts	2,983
Less imputed interest	(863)
Total operating lease liabilities	$ 2,380

Note 2 - Ownership Interests _3

Note 2 - Ownership Interests and Advances (Details Textual) - USD ($) $ in Millions	1 Months Ended			12 Months Ended
	Sep. 30, 2020	May 31, 2019	Jan. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Equity Securities, FV-NI, Unrealized Gain (Loss), Total					$ 4.5
Equity Method Investment Assets Exceed Carrying Value Of Investment				$ 17.9
Intangible Assets [Member]
Equity Method Investment Allocation of Excess Fair Value				15
Goodwill [Member]
Equity Method Investment Allocation of Excess Fair Value				2.9
Sonobi [Member]
Proceeds from Sale of Equity Method Investments	$ 6.6
WebLinc, Inc., QuanticMind, Inc. and Sonobi, Inc. [Member]
Equity Method Investment, Other than Temporary Impairment				11.3
T-Rex Group, Inc [Member]
Equity Method Investment, Other than Temporary Impairment				8.8
Flashtalking, Inc. [Member]
Equity Securities, FV-NI, Unrealized Gain (Loss), Total				1.5
Ownership Interest, Other [Member]
Equity Securities, FV-NI, Unrealized Gain (Loss), Total				0.3
NovaSom [Member]
Equity Method Investment, Other than Temporary Impairment					$ 3
Propeller [Member]
Proceeds from Sale of Equity Method Investments			$ 41.5
Equity Method Investments, Amount in Holdbacks and Escrows				0.7
Equity Method Investment, Realized Gain (Loss) on Disposal, Total				$ 35.1
Transactis [Member]
Proceeds from Sale of Equity Method Investments		$ 57.5
Equity Method Investment, Realized Gain (Loss) on Disposal, Total		$ 50.7

Note 2 - Ownership Interests _4

Note 2 - Ownership Interests and Advances - Schedule of Carrying Value of Ownership Interests (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Equity Method Companies	$ 27,821	$ 34,542
Other Companies	19,951	27,484
Advances to companies (equity method)	2,626	15,103
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures, Total	50,398	77,129
Partnership Interest [Member]
Equity Method Companies	27,550	34,271
Other Companies	19,683	27,031
Private Equity Funds [Member]
Equity Method Companies	271	271
Other Companies	$ 268	$ 453

Note 2 - Ownership Interests _5

Note 2 - Ownership Interests and Advances - Schedule of Equity Method Investment Partner Company Results Of Operation (Details) $ in Thousands	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Current assets	$ 16,063	$ 26,350
Total Assets	69,035	107,577
Current liabilities	3,470	2,429
Total Liabilities and Equity	69,035	107,577
High Traction Stage [Member]
Current assets	104,024	91,968
Non-current assets	26,352	26,231
Total Assets	130,376	118,199
Current liabilities	72,972	80,783
Non-current liabilities	105,506	87,081
Shareholders’ deficit	(48,102)	(49,665)
Total Liabilities and Equity	$ 130,376	$ 118,199
Number of equity method ownership interests	12	13

Note 2 - Ownership Interests _6

Note 2 - Ownership Interests and Advances - Schedule of Results of Operations (Details) - Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue	$ 153,875	$ 145,632
Gross profit	92,039	78,465
Net loss	$ (82,216)	$ (127,007)

Note 3 - Acquisitions of Owne_2

Note 3 - Acquisitions of Ownership Interests (Details Textual) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended	12 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Payments to Acquire Equity Method Investments					$ 7,534	$ 11,640
Equity Method Investments					$ 27,821	34,542
Aktana, Inc. [Member]
Payments to Acquire Equity Method Investments	$ 2,500					1,500
Equity Method Investments	$ 11,700
Syapse, Inc. [Member]
Payments to Acquire Equity Method Investments				$ 4,400		5,000
Equity Method Investments		$ 20,600		20,600
Convertible Bridge Loan			$ 600
meQuilibrium [Member]
Payments to Acquire Equity Method Investments			1,000			1,500
Equity Method Investments			13,000
Trice Medical, Inc. [Member]
Equity Method Investments		10,200		10,200
Convertible Bridge Loan				700
Clutch Holdings [Member]
Payments to Acquire Equity Method Investments		200				400
Equity Method Investments		$ 16,700		$ 16,700
QuanticMind [Member]
Equity Method Investments			13,500
Convertible Bridge Loan			200			600
WebLinc, Inc. [Member]
Equity Method Investments			16,100
Convertible Bridge Loan			$ 100			1,100
Moxe Health Corporation [Member]
Payments to Acquire Equity Method Investments						2,000
Equity Method Investments						5,500
Convertible Bridge Loan						300
Zipnosis [Member]
Payments to Acquire Equity Method Investments						1,500
Equity Method Investments						8,500
Sonobi [Member]
Equity Method Investments						11,400
Convertible Bridge Loan						2,000
NovaSom [Member]
Equity Method Investments						26,400
Convertible Bridge Loan						$ 1,000

Note 5 - Credit Facility and _2

Note 5 - Credit Facility and Convertible Debentures (Details Textual) - USD ($) $ in Thousands	Jul. 31, 2019	Apr. 15, 2019	May 31, 2018	Sep. 30, 2019	[1]	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Repayments of Lines of Credit								$ 0	$ 68,568
Interest Expense, Debt, Total				$ 5,806		$ 5,682	$ 2,535	0	14,023
Debt Instrument, Gain (Loss) from Covenant Liability									5,100
Interest Paid, Excluding Capitalized Interest, Operating Activities								0	$ 11,500
Revolving Credit Facility [Member]
Debt Instrument, Debt Covenants, Cash and Cash Equivalent Threshold								50,000
Revolving Credit Facility [Member] | Line of Credit [Member]
Interest Expense, Debt, Total								$ 14,000
Debt Instrument, Interest Rate, Effective Percentage								15.10%
Interest Paid, Excluding Capitalized Interest, Operating Activities								$ 11,500
Credit Facility [Member] | Revolving Credit Facility [Member] | Payable on the Last Day of the One, Two or Three Month Interest Period [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate			8.50%
Credit Facility [Member] | Revolving Credit Facility [Member] | Payable on the Last Day of the One, Two or Three Month Interest Period [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
LIBOR Floor Rate			1.00%
Credit Facility [Member] | Revolving Credit Facility [Member] | Payable Monthly in Arrears [Member]
Debt Instrument, Basis Spread on Variable Rate			2.00%
Credit Facility [Member] | Revolving Credit Facility [Member] | Payable Monthly in Arrears [Member] | Minimum [Member]
Debt Instrument, Interest Rate, Stated Percentage			7.50%
Credit Facility [Member] | Revolving Credit Facility [Member] | Payable Monthly in Arrears [Member] | Fed Funds Effective Rate Overnight Index Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate			0.50%
Credit Facility [Member] | Revolving Credit Facility [Member] | Payable Monthly in Arrears [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate			1.00%
Amended Credit Facility [Member]
Debt Instrument, Debt Covenants, Cash and Cash Equivalent Threshold			$ 50,000							$ 50,000
Repayments of Lines of Credit		$ 24,000
Line of Credit Facility, Periodic Payment, Interest		$ 2,900
Extinguishment of Debt, Amount	$ 44,500
Interest Expense, Debt, Total	$ 4,100
Long-term Line of Credit, Repayment Feature, Noncurrent			$ 500
[1]	The three months ended December 31, 2019 includes equity income of $1.4 million related to an equity method investment that should have been recorded during the three months ended September 30, 2019. There was no impact on the full year results.

Note 6 - Equity (Details Textua

Note 6 - Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Nov. 07, 2019	Dec. 31, 2020	Dec. 31, 2019	Feb. 28, 2018	Jul. 31, 2015
Stock Repurchase Program, Authorized Amount					$ 25,000
Treasury Stock, Shares, Acquired (in shares)		0	0
Sale of Stock, Individual Ownership, Percent, Maximum				4.99%
Preferred Stock Purchase Right to be Exchanged for Common Stock Above Maximum Ownership Threshold (in shares)				1
Dividends Payable, Amount Per Share (in dollars per share)	$ 1
Dividends, Total	$ 20,700		$ 20,679

Note 7 - Stock-Based Compensa_3

Note 7 - Stock-Based Compensation (Details Textual) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)shares
Share-based Compensation Arrangement by Share-based Payment Award, Number of Award Vesting Types	2
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	0	0
Share-based Payment Arrangement, Expense | $	$ 965	$ 1,237
Cash Liability for Performance-Based Units | $	0
Director [Member]
Share-based Payment Arrangement, Expense | $	1,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $	$ 500	$ 100
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares)	72	174
Share-based Payment Arrangement, Expense, after Tax | $	$ 0	$ 100
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Ending Balance (in shares)	21
Service Based Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in shares)	62	57
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	4 years
Share Based Compensation Arrangement, By Share Based Payment Award, Expiration Term (Year)	8 years
Share-based Payment Arrangement, Expense | $	$ 0	$ 0
Restricted Stock [Member]
Share-based Payment Arrangement, Expense | $		$ 100
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period (in shares)	193	31
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)	10	75
Restricted Stock [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	2 years
Restricted Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	4 years
Performance Stock Unit [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $	$ 700
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Maximum Target Percentage	120.00%
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period (in shares)	100	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)	129	339
Deferred Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period (in shares)	20	0
Percentage of Shares Vested in Lieu of Directors Fees at the Grant Date	100.00%
Portion of Director Fees Matched to Deferred Stock Units.	25.00%
Share-based Compensation Arrangement by Share Based Payment, Deferred award, Vesting Period (Year)	1 year
Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member]
Share-based Payment Arrangement, Expense, after Tax | $	$ 500	$ 1,200
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $	$ 500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)	174	107
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)	139	414
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | $	$ 1,100	$ 1,200
2014 Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	4,100
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	2,800

Note 7 - Stock-Based Compensa_4

Note 7 - Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Stock-based compensation expense	$ 965	$ 1,237
General and Administrative Expense [Member]
Stock-based compensation expense	$ 965	$ 1,237

Note 7 - Stock-Based Compensa_5

Note 7 - Stock-Based Compensation - Schedule of Stock Options Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Options granted, shares (in shares)	0	0
Share-based Payment Arrangement, Option [Member]
Balance, shares (in shares)	179	410
Balance, weighted average exercise price (in dollars per share)	$ 15.27	$ 14.66
Options granted, shares (in shares)	0	0
Options granted, weighted average exercise price (in dollars per share)	$ 0	$ 0
Options exercised, shares (in shares)	0	0
Options exercised, weighted average exercise price (in dollars per share)	$ 0	$ 0
Options canceled/forfeited, shares (in shares)	(134)	(231)
Options canceled/forfeited, weighted average exercise price (in dollars per share)	$ 14.36	$ 14.19
Options exercised, shares (in shares)	0	0
Balance, shares (in shares)	45	179
Balance, weighted average exercise price (in dollars per share)	$ 14.20	$ 15.27
Balance, weighted average remaining contractual life (Year)	2 years 3 months 14 days
Balance, aggregative intrinsic value	$ 0
Options exercisable, shares (in shares)	22
Options exercisable , weighted average exercise price (in dollars per share)	$ 14.48
Options exercisable, weighted average remaining contractual life (Year)	3 years 29 days
Options exercisable, aggregative intrinsic value	$ 0
Shares available for future grant, shares (in shares)	2,515

Note 7 - Stock-Based Compensa_6

Note 7 - Stock-Based Compensation - Schedule of Restricted Stock Units Deferred Stock Units And Performance Units (Details) - Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance (in shares)	287	777
Balance (in dollars per share)	$ 14.44	$ 14.08
Granted (in shares)	313	31
Granted (in dollars per share)	$ 5.89	$ 12.12
Vested (in shares)	(174)	(107)
Vested (in dollars per share)	$ 7.77	$ 11.79
Forfeited (in shares)	(139)	(414)
Forfeited (in dollars per share)	$ 15.24	$ 14.28
Balance (in shares)	287	287
Balance (in dollars per share)	$ 8.78	$ 14.44

Note 8 - Employee Benefit Plan

Note 8 - Employee Benefit Plan (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	5.00%
Defined Contribution Plan, Cost	$ 0.2	$ 0.2

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Federal Income Tax Expense (Benefit), Continuing Operations, Total	$ 0	$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%
Deferred Tax Assets, Operating Loss Carryforwards, Total	$ 362,000
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	37,000
State and Local Income Tax Expense (Benefit), Continuing Operations, Total	$ 0	$ 0

Note 9 - Income Taxes - Schedul

Note 9 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statutory tax (benefit) expense	21.00%	21.00%
Nondeductible expenses	(4.10%)	0.40%
Valuation allowance	(16.90%)	(21.40%)
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%	0.00%

Note 9 - Income Taxes -Schedule

Note 9 - Income Taxes -Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Carrying values of ownership interests and other holdings	$ 38,361	$ 32,760
Tax loss and credit carryforwards	76,023	70,914
Disallowed interest carryforwards	7,292	7,292
Accrued expenses	497	213
Stock-based compensation	302	432
Other	482	604
Deferred Tax Assets, Gross, Total	122,957	112,215
Valuation allowance	(122,957)	(112,215)
Net deferred tax asset	$ 0	$ 0

Note 9 - Income Taxes - Sched_2

Note 9 - Income Taxes - Schedule of Summary of Operating Loss Carryforwards (Details) $ in Thousands	Dec. 31, 2020USD ($)
2021	$ 3,728
2022	48,848
2023	52,512
2024	50,140
2025 and thereafter	170,189
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	$ 325,417

Note 10 - Net Income (Loss) P_3

Note 10 - Net Income (Loss) Per Share (Details Textual) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	45	179
Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)	$ 10.37	$ 10.37
Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)	$ 17.11	$ 18.45
Restricted Stock, Performance-based Stock Units, and Deferred Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	300	300
Convertible Senior Debentures due 2018 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)		800

Note 10 - Net Income (Loss) P_4

Note 10 - Net Income (Loss) Per Share - Schedule of Calculations of Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended																12 Months Ended
	Dec. 31, 2020	[1]	Sep. 30, 2020	[1]	Jun. 30, 2020		Mar. 31, 2020		Dec. 31, 2019	[1]	Sep. 30, 2019	[1]	Jun. 30, 2019		Mar. 31, 2019		Dec. 31, 2020	Dec. 31, 2019
Basic:
Net income (loss)	$ (7,353)		$ (4,343)		$ (9,911)		$ (16,008)		$ (698)		$ (2,497)		$ 36,093		$ 21,663		$ (37,615)	$ 54,561
Basic (in shares)																	20,751	20,636
Basic (in dollars per share)	$ (0.35)	[2]	$ (0.21)	[2]	$ (0.48)	[2]	$ (0.77)	[2]	$ (0.03)	[2]	$ (0.12)	[2]	$ 1.75	[2]	$ 1.05	[2]	$ (1.81)	$ 2.64
Diluted:
Net income (loss)	$ (7,353)		$ (4,343)		$ (9,911)		$ (16,008)		$ (698)		$ (2,497)		$ 36,093		$ 21,663		$ (37,615)	$ 54,561
Diluted (in shares)																	20,751	20,636
Basic (in dollars per share)	$ (0.35)	[2]	$ (0.21)	[2]	$ (0.48)	[2]	$ (0.77)	[2]	$ (0.03)	[2]	$ (0.12)	[2]	$ 1.75	[2]	$ 1.05	[2]	$ (1.81)	$ 2.64
[1]	The three months ended December 31, 2019 includes equity income of $1.4 million related to an equity method investment that should have been recorded during the three months ended September 30, 2019. There was no impact on the full year results.
[2]	Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not add to the annual amounts because of differences in the average common shares outstanding during each period. Additionally, in regard to diluted per share amounts only, quarterly amounts may not add to the annual amounts because of the inclusion of the effect of potentially dilutive securities only in the periods in which such effect would have been dilutive, and because of the adjustments to net income (loss) for the dilutive effect of common stock equivalents and convertible securities at our ownership interests.

Note 12 - Commitments and Con_2

Note 12 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Oct. 31, 2001
Future Annual Payment To Chairman and Chief Executive Officer			$ 650
Deferred Compensation Arrangement with Individual Gain (Loss)			$ 1,700
Deferred Compensation Liability, Current and Noncurrent, Total	$ 1,800
Deferred Compensation Liability, Current, Total	$ 1,500
Minimum [Member]
Long-term Incentive Plan, Bonus Pool Percent	0.20%	1.00%
Maximum [Member]
Long-term Incentive Plan, Bonus Pool Percent	1.30%
Employee Severance [Member]
Restructuring and Related Cost, Expected Cost, Total	$ 2,300
Private Equity Funds [Member]
Guarantor Obligations, Current Carrying Value	$ 3,800

Note 13 - Supplemental Cash F_2

Note 13 - Supplemental Cash Flow Information (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Debt Conversion, Converted Instrument, Amount	$ 6,800	$ 2,300
Interest Paid, Excluding Capitalized Interest, Operating Activities	0	11,500
Income Taxes Paid	$ 0	$ 0

Note 14 - Segment Reporting (De

Note 14 - Segment Reporting (Details Textual)	12 Months Ended
	Dec. 31, 2020
Number of Operating Segments	1
Partner Companies Not Consolidated In Financial Statements	12

Note 14 - Segment Reporting - S

Note 14 - Segment Reporting - Schedule of Active Partner Companies by Segment (Details)		Dec. 31, 2020	Dec. 31, 2019
Aktana, Inc. [Member]
Ownership Interest Under Equity Method, Percent		15.10%	17.80%
Clutch Holdings [Member]
Ownership Interest Under Equity Method, Percent		42.30%	41.20%
Flashtalking, Inc. [Member]
Ownership Interest Under Other Method, Percent		13.40%	10.10%
InfoBionic, Inc. [Member]
Ownership Interest Under Equity Method, Percent		25.20%	25.20%
Lumesis, Inc. [Member]
Ownership Interest Under Equity Method, Percent		43.40%	43.50%
MediaMath, Inc. [Member]
Ownership Interest Under Other Method, Percent		13.30%	13.30%
meQuilibrium [Member]
Ownership Interest Under Equity Method, Percent		32.00%	32.70%
Moxe Health Corporation [Member]
Ownership Interest Under Equity Method, Percent		27.60%	29.90%
Prognos Health, Inc. [Member]
Ownership Interest Under Equity Method, Percent		28.50%	28.70%
QuanticMind [Member]
Ownership Interest Under Equity Method, Percent	[1]	24.20%	24.20%
Syapse, Inc. [Member]
Ownership Interest Under Equity Method, Percent		18.90%	20.00%
T-Rex Group, Inc [Member]
Ownership Interest Under Other Method, Percent		13.50%	13.70%
Trice Medical, Inc. [Member]
Ownership Interest Under Equity Method, Percent		16.60%	16.60%
WebLinc, Inc. [Member]
Ownership Interest Under Equity Method, Percent	[1]	39.90%	38.50%
Zipnosis [Member]
Ownership Interest Under Equity Method, Percent		37.20%	37.70%
[1]	These entities were sold subsequent to December 31, 2020. See Note 16 - Subsequent Events, of the consolidated financials statements.

Note 15 - Selected Quarterly _3

Note 15 - Selected Quarterly Financial Information (Unaudited) (Details Textual) - USD ($) $ in Thousands

3 Months Ended

12 Months Ended

Dec. 31, 2020

[1]

Sep. 30, 2020

[1]

Jun. 30, 2020

Mar. 31, 2020

Dec. 31, 2019

Sep. 30, 2019

[1]

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2020

Dec. 31, 2019

Income (Loss) from Equity Method Investments, Total

$ (5,111)

$ (1,300)

$ (5,277)

$ (9,014)

$ (1,057)

[1]

$ (3,440)

$ 40,497

$ 28,267

$ (20,702)

$ 64,267

Equity Method Investment Income Adjustment [Member]

Income (Loss) from Equity Method Investments, Total

$ 1,400

[1]

The three months ended December 31, 2019 includes equity income of $1.4 million related to an equity method investment that should have been recorded during the three months ended September 30, 2019. There was no impact on the full year results.

Note 15 - Selected Quarterly _4

Note 15 - Selected Quarterly Financial Information (Unaudited) - Schedule of Selected Quarterly Financial Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended																12 Months Ended
	Dec. 31, 2020	[1]	Sep. 30, 2020	[1]	Jun. 30, 2020		Mar. 31, 2020		Dec. 31, 2019	[1]	Sep. 30, 2019	[1]	Jun. 30, 2019		Mar. 31, 2019		Dec. 31, 2020	Dec. 31, 2019
General and administrative expense	$ 1,631		$ 2,275		$ 2,028		$ 3,532		$ 2,060		$ 2,262		$ 2,603		$ 3,057		$ 9,466	$ 9,982
Operating loss	(1,631)		(2,275)		(2,028)		(3,532)		(2,060)		(2,262)		(2,603)		(3,057)		(9,466)	(9,982)
Other income (loss), net	(663)		(820)		(2,658)		(3,567)		2,245		8,777		3,118		(1,885)		(7,708)	12,255
Interest income	52		52		52		105		174		234		763		873		261	2,044
Equity income (loss), net	(5,111)		(1,300)		(5,277)		(9,014)		(1,057)		(3,440)		40,497		28,267		(20,702)	64,267
Net loss before income taxes	(7,353)		(4,343)		(9,911)		(16,008)		(698)		(2,497)		36,093		21,663		(37,615)	54,561
Net income (loss)	$ (7,353)		$ (4,343)		$ (9,911)		$ (16,008)		$ (698)		$ (2,497)		$ 36,093		$ 21,663		$ (37,615)	$ 54,561
Basic (in dollars per share)	$ (0.35)	[2]	$ (0.21)	[2]	$ (0.48)	[2]	$ (0.77)	[2]	$ (0.03)	[2]	$ (0.12)	[2]	$ 1.75	[2]	$ 1.05	[2]	$ (1.81)	$ 2.64
Diluted (in dollars per share)	$ (0.35)	[2]	$ (0.21)	[2]	$ (0.48)	[2]	$ (0.77)	[2]	$ (0.03)	[2]	$ (0.12)	[2]	$ 1.75	[2]	$ 1.05	[2]	$ (1.81)	$ 2.64
Interest expense											$ 5,806		$ 5,682		$ 2,535		$ 0	$ 14,023
[1]	The three months ended December 31, 2019 includes equity income of $1.4 million related to an equity method investment that should have been recorded during the three months ended September 30, 2019. There was no impact on the full year results.
[2]	Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not add to the annual amounts because of differences in the average common shares outstanding during each period. Additionally, in regard to diluted per share amounts only, quarterly amounts may not add to the annual amounts because of the inclusion of the effect of potentially dilutive securities only in the periods in which such effect would have been dilutive, and because of the adjustments to net income (loss) for the dilutive effect of common stock equivalents and convertible securities at our ownership interests.

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - USD ($) $ in Thousands	1 Months Ended
	Feb. 28, 2021	Jan. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Syapse, Inc. [Member]
Equity Method Investment, Ownership Percentage			18.90%	20.00%
Subsequent Event [Member] | Syapse, Inc. [Member]
Equity Method Investment, Ownership Percentage	11.00%
Subsequent Event [Member] | Syapse, Inc. [Member]
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 68,000
Subsequent Event [Member] | WebLinc, Inc. [Member]
Proceeds from Sale of Equity Method Investments		$ 3,200
Disposal Group, Including Discontinued Operation, Period of Contingent Proceeds (Month)		24 months
Subsequent Event [Member] | QuanticMind [Member]
Proceeds from Sale of Equity Method Investments		$ 0